is an IgG4 monoclonal antibody that binds with high affinity and
specificity to IL-17A, a proinflammatory
cytokine.1-3 Ixekizumab does
not bind to ligands IL-17B, IL-17C, IL-17D, IL-17E or IL-17F.4
association between the binding affinity of ixekizumab and efficacy
and safety has not been studied by Lilly.
comparisons can be made regarding the binding affinity of IL-17A to
ixekizumab and the binding affinity of other products to their
targets. This has not been studied by Lilly.
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab
in moderate-to-severe plaque psoriasis. N Engl J Med.
Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an
interleukin-17A specific monoclonal antibody, for the treatment of
biologic-naive patients with active psoriatic arthritis: results from
the 24-week randomised, double-blind, placebo-controlled and active
(adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann
Rheum Dis. 2017;76(1):79-87.
Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of
patients with active psoriatic arthritis and an inadequate response
to tumour necrosis factor inhibitors: results from the 24-week
randomized, double-blind, placebo-controlled period of the SPIRIT-P2
phase 3 trial. Lancet. 2017;389(10086):2317-2327.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Liu L, Lu J, Allan BW, et al. Generation and characterization of
ixekizumab, a humanized monoclonal antibody that neutralizes
interleukin-17A. J Inflamm Res. 2016;9:39-50.
= immunoglobulin G subclass 4
= Eli Lilly and Company